Medicare Advantage Disenrollment Period

Medicare Advantage Disenrollment Period

The Medicare Advantage Disenrollment Period (MADP) is a period that allows Medicare Advantage enrollees to disenroll from their plan and return to Original Medicare. The MADP occurs annually from January 1 to March 31, and during this time, Medicare Advantage enrollees can switch to Original Medicare with or without a Part D plan.

Key features of the Medicare Advantage Disenrollment Period include:

• It only applies to those who are enrolled in a Medicare Advantage plan.

• It allows Medicare Advantage enrollees to switch back to Original Medicare.

• During this period, beneficiaries can also enroll in a stand-alone Part D prescription drug plan if they choose to do so.

• Any changes made during the MADP take effect on the first day of the following month after the changes are made.

For example, if a Medicare Advantage enrollee decides to switch to Original Medicare during the MADP in February, their coverage under Original Medicare will begin on March 1. If they also choose to enroll in a Part D plan during this period, their coverage under the Part D plan will also begin on March 1.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.